These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
216 related items for PubMed ID: 23448847
1. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia. Citrome L. CNS Spectr; 2012 Nov; 17 Suppl 1():1-9. PubMed ID: 23448847 [Abstract] [Full Text] [Related]
2. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment. Morrissette DA, Stahl SM. CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201 [Abstract] [Full Text] [Related]
3. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. Ereshefsky L, Mascarenas CA. J Clin Psychiatry; 2003 Nov; 64 Suppl 16():18-23. PubMed ID: 14680415 [Abstract] [Full Text] [Related]
5. Relapse and rehospitalization: comparing oral and depot antipsychotics. Schooler NR. J Clin Psychiatry; 2003 Nov; 64 Suppl 16():14-7. PubMed ID: 14680414 [Abstract] [Full Text] [Related]
6. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Citrome L. Int J Clin Pract; 2010 Jan; 64(2):216-39. PubMed ID: 19886879 [Abstract] [Full Text] [Related]
7. Improving treatment adherence in patients with schizophrenia. Kane JM. J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990 [Abstract] [Full Text] [Related]
8. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Kane JM. J Clin Psychiatry; 2003 Sep; 64 Suppl 16():34-40. PubMed ID: 14680417 [Abstract] [Full Text] [Related]
9. [Lifelong relapse prevention with antipsychotics in schizophrenia]. Hasan A, Wobrock T. Psychiatr Prax; 2010 Sep; 37(6):268-70. PubMed ID: 20803409 [No Abstract] [Full Text] [Related]
10. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343 [Abstract] [Full Text] [Related]
15. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Woods SW, Gueorguieva RV, Baker CB, Makuch RW. Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728 [Abstract] [Full Text] [Related]
16. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. Kane JM. J Clin Psychiatry; 2006 Sep; 67 Suppl 5():9-14. PubMed ID: 16822091 [Abstract] [Full Text] [Related]
18. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone. Lincoln J, Stewart ME, Preskorn SH. J Psychiatr Pract; 2010 Mar; 16(2):103-14. PubMed ID: 20511734 [Abstract] [Full Text] [Related]
19. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics]. Gutwinski S, Müller P, Koller M. Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015 [Abstract] [Full Text] [Related]